Lung Cancer and BTOG 2022

The Lung Cancer Channel on VJOncology is supported by Takeda, Novocure and AstraZeneca. These supporters have no influence over the production of the content.

View overview page
2:32
Genomic testing for lung cancer in the UK
Sanjay Popat • 31 Jan 2022
2:58
Updates in treating mesothelioma
Sanjay Popat • 31 Jan 2022
5:32
Integrating smoking cessation programs in lung cancer screening
Rachael Murray • 3 Feb 2022
1:35
Lung cancer highlights at BTOG 2022
Frank McCaughan • 1 Feb 2022
1:02
BTOG 2022 highlights: Prehabilitation and psycho-oncology
Samreen Ahmed • 28 Jan 2022
2:41
The increasing role of liquid biopsies in lung cancer screening
Samreen Ahmed • 28 Jan 2022
9:31
Circulating biomarkers for early-stage lung cancer
Frank McCaughan • 1 Feb 2022
2:26
Developments in targeted lung cancer therapies
Shobhit Baijal • 2 Feb 2022
1:29
Future advancements in lung cancer
Shobhit Baijal • 2 Feb 2022
1:26
Optimizing lung cancer outcomes with early diagnosis and prehabilitation
Matthew Evison • 3 Feb 2022
1:40
Approving low dose CT scanning to reduce lung cancer mortality
Frank McCaughan • 1 Feb 2022
3:32
The role of ctDNA in lung cancer screening
Frank McCaughan • 1 Feb 2022
3:27
The benefits of prehabilitation in patient wellbeing
Samreen Ahmed • 28 Jan 2022
3:16
Perioperative therapies in NSCLC
Sanjay Popat • 31 Jan 2022
1:59
Limitations in genetic testing for lung cancer
Neal Navani • 27 Jan 2022
3:25
Strategies to improve lung cancer outcomes
Neal Navani • 27 Jan 2022

The Lung Cancer Channel on VJOncology is supported by Takeda, Novocure and AstraZeneca.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lung Channel, please contact us .

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals